1. expression surface markers
Supplementary S1 A
expression surface markers
Cell line
PATIENT (sex/age)
Tumor type
CD326
CD3
CD44
CD133
CD117
Pe 4/15
M/72
adeno carcinoma 0% 3%
95%
14%
Pe 5/15
M/86
small cell undifferentiated carcinoma  5% B
Pe 4/15
Pe 5/15
ALDH Bright cells (%)
mRNA expression
Pe 4/15
Pe 5/15 C D
Pe 4/15
Pe 5/15
% viability
SCD1
GAPDH 2D 3D
Pe 4/15
Pe 5/15
YAP
TAZ
Pe 4/15
Pe 5/15

2. Supplementary S2 A B **
Nuclear YAP/TAZ
MF-438
Relative mRNA level **

3. Supplementary S3 A F E D C B G N M L I H

4. Supplementary S4
30 µm
CTR
18 µm
MF-438

5. Relative mRNA level Axin2
Supplementary S5
YAP
TAZ
GAPDH
SCD1
RLU TOP/FOP-FLASH
siCTR
siSCD1
RLU 8X-GTIIC B C
Relative mRNA level Axin2
Pe 4/15 ** A *
YAP
TAZ
GAPDH
CTR
C59 D E
CTR **
C59
N° spheroids/CTR **
XAV-939

6. Supplementary S6 A B C D E - WNT + WNT CTR MF-438 ** * N°spheroids/CTR
siCTR
siYAP/TAZ
+ WNT
- WNT **
Viability (A.U.) * ** *
N°spheroids/CTR

7. Supplementary S7 A B C Relative mRNA level Relative mRNA level**
Relative mRNA level
Relative mRNA level
Relative mRNA level ** *
siCTR
siCTR
siβ-TrcP+siSCD1
siaxin1+siSCD1

8. Supplementary S8 scd1/taz scd1/yap scd1/ctgf scd1/birc5 OS MONTHS 1.0
0.8
0.8
0.6
0.6
P=0.024
P=0.013
0.4
0.4
0.2
0.2
Other
yap1_low/scd1_low
Other
taz_low/scd1_low
0.0
0.0 20 40 60 80
100
120 20 40 60 80
100
120 OS
scd1/ctgf
scd1/birc5
1.0
1.0
0.8
0.8
0.6
0.6
P=0.017
P=0.0004
0.4
0.4
0.2
Other
ctgf_low/scd1_low
0.2
Other
birc5_low/scd1_low
0.0
0.0 20 40 60 80
100
120 20 40 60 80
100
120
MONTHS

9. Supplementary S9